Showing results (21-30 of 296) with videos related to
Sort By:
Pageof 30
Prostate Cancer and Prostatic Diseases|June 3, 2018
Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?Landon C Brown, Guru Sonpavde, Andrew J ArmstrongCurrent Clinical Pharmacology|August 25, 2011
Therapy for non-clear cell histologies in renal cancerRhonda L Bitting, John Madden, Andrew J ArmstrongCancer Journal (Sudbury, Mass.)|January 25, 2020
Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment LandscapeEmily N Kinsey, Tian Zhang, Andrew J ArmstrongCurrent Opinion in Urology|April 3, 2008
Clinical endpoints for drug development in prostate cancerVeshana Ramiah, Daniel J George, Andrew J ArmstrongJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2012
Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycinAndrew J Armstrong, Daniel J George, Susan HalabiStem Cell Investigation|November 17, 2022
An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case reportYubin Kang, Andrew J Armstrong, David S HsuReviews in Urology|March 28, 2007
Current standard and investigational approaches to the management of hormone-refractory prostate cancerPrateek Mendiratta, Andrew J Armstrong, Daniel J GeorgeClinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
Precision Medicine Approaches When Prostate Cancer Akts UpTian Zhang, Daniel J George, Andrew J ArmstrongCancer Journal (Sudbury, Mass.)|February 28, 2008
Cell signaling modifiers in prostate cancerFranklin L Chen, Andrew J Armstrong, Daniel J GeorgeProstate Cancer and Prostatic Diseases|October 6, 2022
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancerEdina C Wang, W Robert Lee, Andrew J ArmstrongPageof 30